Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) reported preliminary unaudited revenue results for Q4 and full‑year 2025. Q4 2025 revenue ≈ $11.3M, up ~37% year‑over‑year, including placement of 16 new Growth Direct systems and validation of three customer systems.
Full‑year 2025 revenue is expected to be ≈ $33.6M, up ~20% year‑over‑year, with recurring revenue ≈ $17.8M, up ~15% year‑over‑year. The company placed 28 new Growth Direct systems in 2025 and has cumulatively placed 190 systems with 155 validated.
Results are preliminary and unaudited; final audited results and a webcast with 2026 outlook will be released in Q1 2026. The company will present at the J.P. Morgan Healthcare Conference on Jan 15, 2026.
Positive
- Q4 revenue +37% to approximately $11.3M
- FY 2025 revenue +20% to approximately $33.6M
- Full‑year recurring revenue +15% to approximately $17.8M
- 28 new Growth Direct systems placed in 2025; cumulative 190 systems placed
Negative
- Preliminary results are unaudited and subject to adjustment
- Complete audited financials and detailed GAAP metrics not yet provided
News Market Reaction
On the day this news was published, RPID declined 0.98%, reflecting a mild negative market reaction. Argus tracked a peak move of +20.0% during that session. Argus tracked a trough of -12.7% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $164M at that time. Trading volume was elevated at 2.9x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RPID was down 1.92% pre-news with mixed peer moves: OWLT -8.43%, RCEL -0.87%, SERA -0.96%, LNSR -0.52%, while PROF rose 2.25%, indicating stock-specific rather than sector-wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Conference participation | Neutral | -1.2% | Announced timing and webcast details for J.P. Morgan conference talk. |
| Nov 18 | Financing agreement | Positive | +5.3% | $45M growth capital commitment to support platform scaling and expansion. |
| Nov 07 | Earnings and guidance | Positive | +12.7% | Reported Q3 results, record order, and raised full-year revenue guidance. |
| Oct 30 | Conference participation | Neutral | +1.4% | Stifel healthcare conference appearance with webcast access details. |
| Oct 28 | Earnings scheduling | Neutral | -1.4% | Set date and webcast for upcoming Q3 2025 earnings release. |
Positive operational and financing updates have recently aligned with favorable price reactions, while neutral conference notices saw modest moves, indicating the stock has responded constructively to concrete growth signals.
Over the past six months, Rapid Micro Biosystems announced multiple catalysts. A Q3 2025 earnings release with raised full-year revenue guidance to at least $33.0 million and record system orders saw a strong positive reaction. A $45 million growth capital commitment from Trinity Capital also aligned with a positive move. Conference participation announcements in October 2025 and a J.P. Morgan presentation notice in January 2026 produced only modest price changes, underscoring that investors have focused more on concrete financial performance and funding milestones than on event logistics.
Market Pulse Summary
This announcement highlights record preliminary Q4 and full-year 2025 revenue for Rapid Micro Biosystems, with total revenue of $33.6 million and recurring revenue of $17.8 million. Growth in Growth Direct system placements and validations underscores ongoing commercial adoption. These figures follow earlier guidance raises and a $45.0 million debt facility that strengthened liquidity. Investors may watch the audited results, margin trends, cash usage, and 2026 outlook when full financials are released later in the first quarter of 2026.
AI-generated analysis. Not financial advice.
- Fourth quarter 2025 total revenue expected to be approximately
$11.3 million , representing growth of approximately37% compared to the prior-year period. - Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing network.
- Full year 2025 total revenue expected to be approximately
$33.6 million , representing growth of approximately20% compared to the prior year.
LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced preliminary unaudited fourth quarter and full year 2025 revenue.
For the fourth quarter of 2025, the Company expects record revenue of approximately
For the full year 2025, the Company expects revenue of approximately
“We are pleased to report record results for the fourth quarter that exceeded our raised guidance issued in November,” said Robert Spignesi, President and CEO. “For the full-year 2025, broad-based strength across systems, consumables and services delivered
“As we enter 2026, we believe the Company is well-positioned for continued growth supported by our proven track record of consistent execution, validation of the Growth Direct platform through multi-system and follow-on customer orders, and the further advancement of our global strategic partnership with MilliporeSigma.”
The Company plans to announce complete financial results for the fourth quarter and full year 2025 and host a webcast to discuss those results as well as its 2026 outlook later in the first quarter of 2026.
The preliminary financial results described herein have not been audited and are subject to adjustment based on the Company’s completion of year-end financial close processes.
Presentation at J.P. Morgan Healthcare Conference
The Company is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 2:15 p.m. Eastern Time (11:15 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed HERE. The webcast will then be archived and available for replay for at least 30 days after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Available Information
Rapid Micro Biosystems announces material information to the public about the Company, its products and services, and other matters through a variety of means, including filings with the U.S. Securities and Exchange Commission (“SEC”), press releases, public conference calls, webcasts, the investor relations section of the Company website at investors.rapidmicrobio.com, and the Company’s X (formerly known as Twitter) account @rapidmicrobio in order to achieve broad, non-exclusionary distribution of information to the public and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s expected results for the fourth quarter and full year 2025, including with respect to revenue and number of Growth Direct placements; and the Company's growth outlook in future periods.
In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company's ability to fulfill customer orders on its anticipated timelines or at all; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
What did Rapid Micro Biosystems (RPID) report for Q4 2025 revenue?
What is Rapid Micro Biosystems' full‑year 2025 revenue and recurring revenue (RPID)?
How many Growth Direct systems did Rapid Micro Biosystems place in 2025 (RPID)?
Are Rapid Micro Biosystems' (RPID) Q4 and FY2025 results final?
When will Rapid Micro Biosystems (RPID) discuss full Q4 and FY2025 results and outlook?
When is Rapid Micro Biosystems (RPID) presenting at the J.P. Morgan Healthcare Conference?
